ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronEye IconIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailMenu BurgerPositive ArrowIcon PrintIcon SearchSite TitleTitle ChevronIcon Twitter
Health Technology

JCR Pharmaceuticals Co., Ltd.

Business Summary

JCR Pharmaceuticals Co., Ltd. engages in the manufacture and sale of pharmaceutical products. It operates through the following segments: Pharmaceutical Business; and Medical and Research Equipment Business. The Pharmaceutical Business segment deals with the manufacture, purchase, and sale of ethical drugs, active pharmaceutical ingredients, and raw materials. The Medical and Research Equipment Business segment sells medical devices and laboratory equipment. The company was founded by Shin Ashida on September 13, 1975 and is headquartered in Ashiya, Japan.

Financial Highlights

Mar 2019 JPYUSD
Revenue23,160M208.84M
Gross Profit16,593M149.62M
Operating income4,968M44.79M
Income before tax4,928M44.43M
Net income3,714M33.49M
EBITDA6,311M56.90M
Diluted EPS119.951.08
Dividends Per Share300.27
Total Assets42,956M388.09M
Total liabilities12,079M109.12M
Total equity30,685M277.22M
Operating cash flow3,905M35.21M
Currency in JPYCurrency in USD

Historical Data

 Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019
Revenue 16,855.65M 17,438.37M 18,085.03M 20,594M 23,160M
Gross Profit 11,114.72M 10,978.95M 12,353.31M 14,466M 16,593M
Operating income 2,067.98M 2,152.77M 2,362.00M 3,785M 4,968M
Income before tax 2,334.31M 2,459.25M 2,492.78M 3,895M 4,928M
Net income 1,682.36M 1,789.47M 1,863.17M 3,069M 3,714M
EBITDA 3,420.37M 3,560.42M 3,809.54M 5,167M 6,311M
Diluted EPS 52.53 55.81 58.61 98.10 119.95
Dividends Per Share 18.50 22 22 26 30
Total Assets 34,086.05M 35,346.79M 36,385.03M 38,737M 42,956M
Total liabilities 7,821.16M 8,284.05M 8,799.17M 11,206M 12,079M
Total equity 26,264.25M 27,061.98M 27,585.00M 27,343M 30,685M
Operating cash flow 499.05M 2,201.74M 2,651.34M 3,133M 3,905M
 Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019
Revenue 153.43M 145.21M 167.00M 185.81M 208.84M
Gross Profit 101.17M 91.42M 114.07M 130.52M 149.62M
Operating income 18.82M 17.92M 21.81M 34.15M 44.79M
Income before tax 21.24M 20.47M 23.02M 35.14M 44.43M
Net income 15.31M 14.90M 17.20M 27.69M 33.49M
EBITDA 31.13M 29.64M 35.17M 46.61M 56.90M
Diluted EPS 0.47 0.46 0.54 0.88 1.08
Dividends Per Share 0.16 0.18 0.20 0.23 0.27
Total Assets 284.22M 314.48M 326.52M 364.24M 388.09M
Total liabilities 65.21M 73.70M 78.96M 105.36M 109.12M
Total equity 219.00M 240.77M 247.55M 257.10M 277.22M
Operating cash flow 4.54M 18.33M 24.48M 28.26M 35.21M

Valuation Measures

Mar 2019
PER54.02
ROA9.09%
ROE12.80%
Operating margin21.45%
Profit margin16.03%

Key executives

  • Chairman, President, Chief Executive Officer & COO: Shin Ashida
  • Executive Officer & General Manager-Administration: Akihiro Haguchi
  • Executive Officer & General Manager-Research: Toru Hirado
  • Executive Officer & GM-Corporate Planning: Yutaka Honda
  • Executive Officer & GM-Research Planning: Hiroyuki Sonoda

Shareholders

  • Medipal Holdings Corp. (22.4%)
  • Kissei Pharmaceutical Co., Ltd. (11.7%)
  • ASHIDA FAMILY (7.6%)
  • JCR Pharmaceuticals Co., Ltd. (4.6%)
  • ASHIDA SHIN (3.6%)
  • Asset Management One Co., Ltd. (3.3%)
  • Sumitomo Dainippon Pharma Co., Ltd. (2.6%)
  • Mochida Pharmaceutical Co., Ltd. (1.6%)
  • The Vanguard Group, Inc. (1.2%)
  • Nomura Asset Management Co., Ltd. (1.0%)

Contact Details

Related Companies

  • JCR International SA
  • Jcr Pharmaceuticals Employee Incentive Plan
  • JCR Pharmaceuticals Employee Stock Ownership Plan
  • Dainippon Sumitomo Pharma Co. Ltd. /HGH Business/

Competitors

  • Ascendis Pharma A/S Sponsored ADR
  • Denali Therapeutics Inc.
  • CORESTEM INC.
Last Updated on 24 Jan, 2020

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Get Unlimited access

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends January 31st

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to the Nikkei Asian Review has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media